Our partner is focused on developing next-generation therapies using their peptide technology. Their innovative approach targets specific disease-causing proteins, particularly in cancer, to deliver more effective and precise treatments, aiming to improve patient outcomes.

This influential hire provided guidance to programs across the portfolio aimed at developing several highly novel peptide therapeutics. They helped drive programs through IND-enabling studies into clinical development and beyond by integrating science, medicine, and business considerations. They also collaborated with Finance to help track and forecast spending for programs.